repaglinide

(redirected from Novonorm)
Also found in: Medical.
Related to Novonorm: repaglinide, Prandin

re·pag·li·nide

 (rĭ-păg′lə-nīd′)
n.
An oral hypoglycemic drug, C27H36N2O4, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes.

[re(lease) + pa(ncreas) + -glinide, antidiabetic drug suff. (shortening of -glitinide, from (me)gli(ti)nide, compound class to which it belongs).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

repaglinide

n repaglinida
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Hussein, "Evaluation of the effects of glimepiride (Amaryl) and repaglinide (novoNorm) on atherosclerosis progression in high cholesterol-fed male rabbits," Journal of Cardiovascular Disease Research, vol.
Cette extension permettra la mise en place d'un processus de granulation de la matiere premiere de Novoformine ainsi que la production locale de NovoNorm, insulino-secretagogue de derniere generation.
Repaglinide Accord is a generic of Danish Novo Nordisk's (CPH:NOVO B) NovoNorm, which has been approved in the European Union (EU) since August 1998.